FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

David Nicolau

Research Profile

Chemicals & Drugs

Procedures

Concepts & Ideas

Living Beings

Physiology

Bacterial Drug Resistance

Disorders

Co-author Network

Publications

TOP 3
Pamela R Tessier; David P Nicolau
In Vitro Activity of Novel Gyrase Inhibitors against a Highly Resistant Population of Pseudomonas aeruginosa.
Amira A Bhalodi; Rebecca A Keel; Thomas P Lodise; David P Nicolau; Richard Quintiliani; Joseph L Kuti
Pharmacokinetics of doripenem in infected patients treated within and outside the intensive care unit.
Lucinda M Lamb; Jared L Crandon; David P Nicolau
Pharmacokinetic and pharmacodynamic evaluation of P-873 versus Klebsiella pneumoniae in a neutropenic murine thigh infection model.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of David Nicolau (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Pamela R Tessier; David P Nicolau
In Vitro Activity of Novel Gyrase Inhibitors against a Highly Resistant Population of Pseudomonas aeruginosa.
Antimicrobial agents and chemotherapy 2013;57(6):2887-9.
2013: Amira A Bhalodi; Rebecca A Keel; Thomas P Lodise; David P Nicolau; Richard Quintiliani; Joseph L Kuti
Pharmacokinetics of doripenem in infected patients treated within and outside the intensive care unit.
The Annals of pharmacotherapy 2013;47(5):617-27.
2013: Lucinda M Lamb; Jared L Crandon; David P Nicolau
Pharmacokinetic and pharmacodynamic evaluation of P-873 versus Klebsiella pneumoniae in a neutropenic murine thigh infection model.
Antimicrobial agents and chemotherapy 2013;57(4):1971-3.
2013: Dora E Wiskirchen; Seth T Housman; David P Nicolau; Richard Quintiliani; Joseph L Kuti
Comparative pharmacokinetics, pharmacodynamics, and tolerability of ertapenem 1 gram/day administered as a rapid 5-minute infusion versus the standard 30-minute infusion in healthy adult volunteers.
Pharmacotherapy 2013;33(3):266-74.
2013: Amira A Bhalodi; David P Nicolau; Pavlos K Papasavas; Darren S Tishler; Joseph L Kuti
Pharmacokinetics of intravenous linezolid in moderately to morbidly obese adults.
Antimicrobial agents and chemotherapy 2013;57(3):1144-9.
2013: Mao Hagihara; Christina Sutherland; David P Nicolau
Development of HPLC methods for the determination of vancomycin in human plasma, mouse serum and bronchoalveolar lavage fluid.
Journal of chromatographic science 2013;51(3):201-7.
2013: Mary A Banevicius; Barry Hafkin; Nachum Kaplan; David P Nicolau
Pharmacokinetics, pharmacodynamics and efficacy of novel FabI inhibitor AFN-1252 against MSSA and MRSA in the murine thigh infection model.
Journal of chemotherapy (Florence, Italy) 2013;25(1):26-31.
2013: Mao Hagihara; Jared L Crandon; Carl M Urban; David P Nicolau
KPC presence in Pseudomonas aeruginosa has minimal impact on the in vivo efficacy of carbapenem therapy.
Antimicrobial agents and chemotherapy 2013;57(2):1086-8.
2013: Pamela R Tessier; David P Nicolau
Tigecycline displays in vivo bactericidal activity against extended-spectrum-β-lactamase-producing Enterobacteriaceae after 72-hour exposure period.
Antimicrobial agents and chemotherapy 2013;57(1):640-2.
2012: Amira A Bhalodi; Donald Biek; Jared L Crandon; David P Nicolau
Efficacy of ceftaroline fosamil in a staphylococcal murine pneumonia model.
Antimicrobial agents and chemotherapy 2012;56(12):6160-5.
2012: Jared L Crandon; Wright W Nichols; Mary Anne Banevicius; Marie-Eve Beaudoin; Virna J Schuck; M Angela Tanudra; David P Nicolau
Comparative in vitro and in vivo efficacies of human simulated doses of ceftazidime and ceftazidime-avibactam against Pseudomonas aeruginosa.
Antimicrobial agents and chemotherapy 2012;56(12):6137-46.
2012: Ashley M Wilde; Michael D Nailor; David P Nicolau; Joseph L Kuti
Inappropriate antibiotic use due to decreased compliance with a ventilator-associated pneumonia computerized clinical pathway: implications for continuing education and prospective feedback.
Pharmacotherapy 2012;32(8):755-63.
2012: Kathryn J Eagye; Mary A Banevicius; David P Nicolau
Pseudomonas aeruginosa is not just in the intensive care unit any more: implications for empirical therapy.
Critical care medicine 2012;40(4):1329-32.
2012: G H Furtado; Joseph L Kuti; D E Wiskirchen; David P Nicolau
Performance of the PIRO score for predicting mortality in patients with ventilator-associated pneumonia.
Anaesthesia and intensive care 2012;40(2):285-91.
2012: Mao Hagihara; Joseph L Kuti; David P Nicolau
Predicting doripenem susceptibility based on meropenem and imipenem interpretation for Pseudomonas aeruginosa.
Diagnostic microbiology and infectious disease 2012;72(3):258-62.
2012: David P Nicolau; Christina Sutherland; Donna Winget; Robert P Baughman
Bronchopulmonary pharmacokinetic and pharmacodynamic profiles of levofloxacin 750 mg once daily in adults undergoing treatment for acute exacerbation of chronic bronchitis.
Pulmonary pharmacology & therapeutics 2012;25(1):94-8.
2011: Dora E Wiskirchen; Joseph L Kuti; David P Nicolau
Acute physiology and chronic health evaluation II score is a better predictor of mortality than IBMP-10 in patients with ventilator-associated pneumonia.
Surgical infections 2011;12(5):385-90.
2011: Seth T Housman; Joseph L Kuti; David P Nicolau
Optimizing antibiotic pharmacodynamics in hospital-acquired and ventilator-acquired bacterial pneumonia.
Clinics in chest medicine 2011;32(3):439-50.
2011: Dora E Wiskirchen; Ashley Shepard; Joseph L Kuti; David P Nicolau
Determination of tissue penetration and pharmacokinetics of linezolid in patients with diabetic foot infections using in vivo microdialysis.
Antimicrobial agents and chemotherapy 2011;55(9):4170-5.
2011: Rebecca A Keel; Jared L Crandon; David P Nicolau
Efficacy of human simulated exposures of ceftaroline administered at 600 milligrams every 12 hours against phenotypically diverse Staphylococcus aureus isolates.
Antimicrobial agents and chemotherapy 2011;55(9):4028-32.
2011: Aryun Kim; David P Nicolau; Joseph L Kuti
Hospital costs and outcomes among intravenous antifungal therapies for patients with invasive aspergillosis in the United States.
Mycoses 2011;54(5):e301-12.
2011: Dora E Wiskirchen; Gregory Williams; Jared L Crandon; Guilherme H Furtado; David P Nicolau
In vivo efficacy of a human-simulated regimen of ceftaroline combined with NXL104 against extended-spectrum-beta-lactamase (ESBL)-producing and non-ESBL-producing Enterobacteriaceae.
Antimicrobial agents and chemotherapy 2011;55(7):3220-5.
2011: Rebecca A Keel; Charlotte Kloft; R Frederic Knauft; Marianne Muhlebach; David P Nicolau; J Samuel Pope; Andre Schaeftlein; Joseph L Kuti
Pharmacokinetics of intravenous and oral linezolid in adults with cystic fibrosis.
Antimicrobial agents and chemotherapy 2011;55(7):3393-8.
2011: Kathryn Eagye; David P Nicolau
Change in antipseudomonal carbapenem susceptibility in 25 hospitals across 9 years is not associated with the use of ertapenem.
The Journal of antimicrobial chemotherapy 2011;66(6):1392-5.
2011: Catharine C Bulik; David P Nicolau
Double-carbapenem therapy for carbapenemase-producing Klebsiella pneumoniae.
Antimicrobial agents and chemotherapy 2011;55(6):3002-4.
2011: Christina A Sutherland; David P Nicolau; Joseph L Kuti
Development of an HPLC method for the determination of anidulafungin in human plasma and saline.
Journal of chromatographic science 2011;49(5):397-400.
2011: Kathryn Eagye; David P Nicolau
Fluoroquinolone use is not associated with the change in imipenem susceptibility of Pseudomonas aeruginosa in 25 hospitals.
Advances in therapy 2011;28(4):326-33.
2011: Dora E Wiskirchen; Pornpan Koomanachai; Anthony M Nicasio; David P Nicolau; Joseph L Kuti
In vitro pharmacodynamics of simulated pulmonary exposures of tigecycline alone and in combination against Klebsiella pneumoniae isolates producing a KPC carbapenemase.
Antimicrobial agents and chemotherapy 2011;55(4):1420-7.
2011: Jared L Crandon; Robert E Ariano; Sheryl A Zelenitsky; Anthony M Nicasio; Joseph L Kuti; David P Nicolau
Optimization of meropenem dosage in the critically ill population based on renal function.
Intensive care medicine 2011;37(4):632-8.
2011: David P Nicolau
Current challenges in the management of the infected patient.
Current opinion in infectious diseases 2011;24 Suppl 1():S1-10.
2011: Rebecca A Keel; Sheryl A Zelenitsky; George G Zhanel; David P Nicolau
Pharmacodynamic profiling of antimicrobials against Gram-negative respiratory isolates from Canadian hospitals.
The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie médicale / AMMI Canada 2011;22(4):132-6.
2011: Pornpan Koomanachai; Rebecca A Keel; Kelly K Johnson-Arbor; Larry A Suecof; David P Nicolau; Joseph L Kuti
Linezolid penetration into wound tissue of two diabetic patients before and after hyperbaric oxygen therapy.
Undersea & hyperbaric medicine : journal of the Undersea and Hyperbaric Medical Society, Inc 2011;38(1):11-6.
2011: Jared L Crandon; David P Nicolau
Pharmacodynamic approaches to optimizing beta-lactam therapy.
Critical care clinics 2011;27(1):77-93.
2010: Catharine C Bulik; Dora E Wiskirchen; Ashley Shepard; Christina A Sutherland; Joseph L Kuti; David P Nicolau
Tissue penetration and pharmacokinetics of tigecycline in diabetic patients with chronic wound infections described by using in vivo microdialysis.
Antimicrobial agents and chemotherapy 2010;54(12):5209-13.
2010: Jared L Crandon; Joseph L Kuti; David P Nicolau
Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.
Antimicrobial agents and chemotherapy 2010;54(12):5115-9.
2010: Rebecca A Keel; Christina A Sutherland; Jaber Aslanzadeh; David P Nicolau; Joseph L Kuti
Correlation between vancomycin and daptomycin MIC values for methicillin-susceptible and methicillin-resistant Staphylococcus aureus by 3 testing methodologies.
Diagnostic microbiology and infectious disease 2010;68(3):326-9.
2010: Catharine C Bulik; David P Nicolau
In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemase- producing Klebsiella pneumoniae.
Antimicrobial agents and chemotherapy 2010;54(10):4112-5.
2010: Catharine C Bulik; Kathy A Fauntleroy; Stephen G Jenkins; Mayssa Abuali; Vincent J Labombardi; David P Nicolau; Joseph L Kuti
Comparison of meropenem MICs and susceptibilities for carbapenemase-producing Klebsiella pneumoniae isolates by various testing methods.
Journal of clinical microbiology 2010;48(7):2402-6.
2010: Kathryn J Eagye; David P Nicolau
Absence of association between use of ertapenem and change in antipseudomonal carbapenem susceptibility rates in 25 hospitals.
Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America 2010;31(5):485-90.
2010: Pornpan Koomanachai; Catharine C Bulik; Joseph L Kuti; David P Nicolau
Pharmacodynamic modeling of intravenous antibiotics against gram-negative bacteria collected in the United States.
Clinical therapeutics 2010;32(4):766-79.
2010: Joseph L Kuti; David P Nicolau
Optimal cefepime and meropenem dosing for ventilator-associated pneumonia patients with reduced renal function: an update to our clinical pathway.
Journal of critical care 2010;25(1):155-6.
2010: Jared L Crandon; Catharine C Bulik; Joseph L Kuti; David P Nicolau
Clinical pharmacodynamics of cefepime in patients infected with Pseudomonas aeruginosa.
Antimicrobial agents and chemotherapy 2010;54(3):1111-6.
2010: Anthony M Nicasio; Kathryn J Eagye; David P Nicolau; Eric Shore; Marc Palter; Judith Pepe; Joseph L Kuti
Pharmacodynamic-based clinical pathway for empiric antibiotic choice in patients with ventilator-associated pneumonia.
Journal of critical care 2010;25(1):69-77.
2010: Catharine C Bulik; Henry Christensen; Peng Li; Christina A Sutherland; David P Nicolau; Joseph L Kuti
Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
Antimicrobial agents and chemotherapy 2010;54(2):804-10.
2010: David P Nicolau; Gary E Stein
Therapeutic options for diabetic foot infections: a review with an emphasis on tissue penetration characteristics.
Journal of the American Podiatric Medical Association 2010;100(1):52-63.
2010: Catharine C Bulik; Henry Christensen; David P Nicolau
In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance.
Antimicrobial agents and chemotherapy 2010;54(1):557-9.
2009: Pornpan Koomanachai; Jared L Crandon; David P Nicolau
Newer developments in the treatment of Gram-positive infections.
Expert opinion on pharmacotherapy 2009;10(17):2829-43.
2009: Jared L Crandon; Mary Anne Banevicius; Annie F Fang; Penelope H Crownover; R Fredrick Knauft; J Samuel Pope; John H Russomanno; Eric Shore; David P Nicolau; Joseph L Kuti
Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults.
Antimicrobial agents and chemotherapy 2009;53(12):5102-7.
2009: Pornpan Koomanachai; Jared L Crandon; Mary Anne Banevicius; Li Peng; David P Nicolau
Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model.
Antimicrobial agents and chemotherapy 2009;53(12):5060-3.
2009: Aryun Kim; Joseph L Kuti; David P Nicolau
Probability of pharmacodynamic target attainment with standard and prolonged-infusion antibiotic regimens for empiric therapy in adults with hospital-acquired pneumonia.
Clinical therapeutics 2009;31(11):2765-78.
2009: Kathryn Eagye; Joseph L Kuti; Christina A Sutherland; Henry Christensen; David P Nicolau
In vitro activity and pharmacodynamics of commonly used antibiotics against adult systemic isolates of Escherichia coli and Pseudomonas aeruginosa at Forty US Hospitals.
Clinical therapeutics 2009;31(11):2678-88.
2009: Paschalina Kontou; Joseph L Kuti; David P Nicolau
Validation of the Infectious Diseases Society of America/American Thoracic Society criteria to predict severe community-acquired pneumonia caused by Streptococcus pneumoniae.
The American journal of emergency medicine 2009;27(8):968-74.
2009: Jared L Crandon; Catharine C Bulik; David P Nicolau
In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa.
Antimicrobial agents and chemotherapy 2009;53(10):4352-6.
2009: Jared L Crandon; Aryun Kim; David P Nicolau
Comparison of tigecycline penetration into the epithelial lining fluid of infected and uninfected murine lungs.
The Journal of antimicrobial chemotherapy 2009;64(4):837-9.
2009: Kathryn J Eagye; David P Nicolau
Deep and organ/space infections in patients undergoing elective colorectal surgery: incidence and impact on hospital length of stay and costs.
American journal of surgery 2009;198(3):359-67.
2009: Catharine C Bulik; Joseph L Kuti; David P Nicolau
Clostridium difficile infection--not just a burden anymore.
Connecticut medicine 2009;73(7):407-11.
2009: Kathryn Eagye; Aryun Kim; Somvadee Laohavaleeson; Joseph L Kuti; David P Nicolau
Surgical site infections: does inadequate antibiotic therapy affect patient outcomes?
Surgical infections 2009;10(4):323-31.
2009: Kathryn J Eagye; Joseph L Kuti; David P Nicolau
Risk factors and outcomes associated with isolation of meropenem high-level-resistant Pseudomonas aeruginosa.
Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America 2009;30(8):746-52.
2009: Anthony M Nicasio; Jared L Crandon; David P Nicolau
In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates.
Antimicrobial agents and chemotherapy 2009;53(7):2756-61.
2009: Joseph L Kuti; Anthony M Nicasio; Christina A Sutherland; David P Nicolau
Elevated vancomycin minimum inhibitory concentrations among methicillin-resistant Staphylococcus aureus isolated from patients with ventilator-associated pneumonia at a Connecticut hospital.
Connecticut medicine 2009;73(6):337-40.
2009: David P Nicolau
Management of complicated infections in the era of antimicrobial resistance: the role of tigecycline.
Expert opinion on pharmacotherapy 2009;10(7):1213-22.
2009: Pornpan Koomanachai; Aryun Kim; David P Nicolau
Pharmacodynamic evaluation of tigecycline against Acinetobacter baumannii in a murine pneumonia model.
The Journal of antimicrobial chemotherapy 2009;63(5):982-7.
2009: Anthony M Nicasio; Robert E Ariano; Sheryl A Zelenitsky; Aryun Kim; Jared L Crandon; Joseph L Kuti; David P Nicolau
Population pharmacokinetics of high-dose, prolonged-infusion cefepime in adult critically ill patients with ventilator-associated pneumonia.
Antimicrobial agents and chemotherapy 2009;53(4):1476-81.
2009: Pornpan Koomanachai; Jared L Crandon; Joseph L Kuti; David P Nicolau
Comparative pharmacodynamics for intravenous antibiotics against Gram-negative bacteria in Europe between 2002 and 2006: a report from the OPTAMA program.
International journal of antimicrobial agents 2009;33(4):348-53.
2009: Jared L Crandon; Mary Anne Banevicius; David P Nicolau
Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.
Antimicrobial agents and chemotherapy 2009;53(3):1165-9.
2009: Anthony M Nicasio; Pamela R Tessier; David P Nicolau; R Fredrick Knauft; John Russomanno; Eric Shore; Joseph L Kuti
Bronchopulmonary disposition of micafungin in healthy adult volunteers.
Antimicrobial agents and chemotherapy 2009;53(3):1218-20.
2009: Kathryn J Eagye; David P Nicolau; Joseph L Kuti
Impact of superinfection on hospital length of stay and costs in patients with ventilator-associated pneumonia.
Seminars in respiratory and critical care medicine 2009;30(1):116-23.
2009: Joseph L Kuti; Eric Shore; Marc Palter; David P Nicolau
Tackling empirical antibiotic therapy for ventilator-associated pneumonia in your ICU: guidance for implementing the guidelines.
Seminars in respiratory and critical care medicine 2009;30(1):102-15.
2009: Jared L Crandon; Joseph L Kuti; Ronald N Jones; David P Nicolau
Comparison of 2002-2006 OPTAMA programs for US hospitals: focus on gram-negative resistance.
The Annals of pharmacotherapy 2009;43(2):220-7.
2008: Somvadee Laohavaleeson; Steven L Barriere; David P Nicolau; Joseph L Kuti
Cost-effectiveness of telavancin versus vancomycin for treatment of complicated skin and skin structure infections.
Pharmacotherapy 2008;28(12):1471-82.
2008: Aryun Kim; Larry A Suecof; Christina A Sutherland; Lihong Gao; Joseph L Kuti; David P Nicolau
In vivo microdialysis study of the penetration of daptomycin into soft tissues in diabetic versus healthy volunteers.
Antimicrobial agents and chemotherapy 2008;52(11):3941-6.
2008: David P Nicolau
Pharmacokinetic and pharmacodynamic properties of meropenem.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2008;47 Suppl 1():S32-40.
2008: Anthony M Nicasio; Joseph L Kuti; Jaber Aslanzadeh; David P Nicolau
Influence of automated screening and confirmation of extended-spectrum beta-lactamase-producing members of the Enterobacteriaceae on prescribing of antibiotics.
Journal of medical microbiology 2008;57(Pt 9):1147-51.
2008: Aryun Kim; Mary Anne Banevicius; David P Nicolau
In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures.
Antimicrobial agents and chemotherapy 2008;52(7):2497-502.
2008: Somvadee Laohavaleeson; Pamela R Tessier; David P Nicolau
Pharmacodynamic characterization of ceftobiprole in experimental pneumonia caused by phenotypically diverse Staphylococcus aureus strains.
Antimicrobial agents and chemotherapy 2008;52(7):2389-94.
2008: Jared Crandon; David P Nicolau
Oritavancin: a potential weapon in the battle against serious Gram-positive pathogens.
Future microbiology 2008;3(3):251-63.
2008: David P Nicolau
Bugs versus drugs: what is the pharmacist's challenge?
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 2008;65(9 Suppl 2):S2-3.
2008: Shin-Woo Kim; Joseph L Kuti; David P Nicolau
Inhaled antimicrobial therapies for respiratory infections.
Current infectious disease reports 2008;10(1):29-36.
2008: Joseph L Kuti; Michael Dowzicky; David P Nicolau
Pharmacodynamic performance of tigecycline versus common intravenous antibiotics for the empiric treatment of complicated skin and skin structure infections.
Surgical infections 2008;9(1):57-66.
2008: Joseph L Kuti; M Dowzicky; David P Nicolau
A pharmacodynamic simulation to assess tigecycline efficacy for hospital-acquired pneumonia compared with other common intravenous antibiotics.
Journal of chemotherapy (Florence, Italy) 2008;20(1):69-76.
2008: Joseph L Kuti; Carlos R V Kiffer; Caio Mendes; David P Nicolau
Pharmacodynamic comparison of linezolid, teicoplanin and vancomycin against clinical isolates of Staphylococcus aureus and coagulase-negative staphylococci collected from hospitals in Brazil.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2008;14(2):116-23.
2008: Somvadee Laohavaleeson; Karen Lolans; Joseph L Kuti; John P Quinn; David P Nicolau
Expression of the MexXY-OprM efflux system in Pseudomonas aeruginosa with discordant cefepime/ceftazidime susceptibility profiles.
Infection and drug resistance 2008;1():51-5.
2008: David P Nicolau
Pharmacodynamic optimization of beta-lactams in the patient care setting.
Critical care (London, England) 2008;12 Suppl 4():S2.
2007: Aryun Kim; Christina A Sutherland; Joseph L Kuti; David P Nicolau
Optimal dosing of piperacillin-tazobactam for the treatment of Pseudomonas aeruginosa infections: prolonged or continuous infusion?
Pharmacotherapy 2007;27(11):1490-7.
2007: Hui Wang; Bo Zhang; Yuxing Ni; Joseph L Kuti; Baiyi Chen; Minjun Chen; David P Nicolau
Pharmacodynamic target attainment of seven antimicrobials against Gram-negative bacteria collected from China in 2003 and 2004.
International journal of antimicrobial agents 2007;30(5):452-7.
2007: David P Nicolau; Heather K Sun; Elyse Seltzer; Mary Buckwalter; James A Dowell
Pharmacokinetics of dalbavancin in plasma and skin blister fluid.
The Journal of antimicrobial chemotherapy 2007;60(3):681-4.
2007: C Andrew DeRyke; Joseph L Kuti; David P Nicolau
Reevaluation of current susceptibility breakpoints for Gram-negative rods based on pharmacodynamic assessment.
Diagnostic microbiology and infectious disease 2007;58(3):337-44.
2007: Christina Sutherland; David P Nicolau
Development of an HPLC method for the determination of doripenem in human and mouse serum.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2007;853(1-2):123-6.
2007: Anthony M Nicasio; Richard Quintiliani; C Andrew DeRyke; Joseph L Kuti; David P Nicolau
Treatment of Serratia marcescens meningitis with prolonged infusion of meropenem.
The Annals of pharmacotherapy 2007;41(6):1077-81.
2007: L Santos Filho; Kathryn Eagye; Joseph L Kuti; David P Nicolau
Addressing resistance evolution in Pseudomonas aeruginosa using pharmacodynamic modelling: application to meropenem dosage and combination therapy.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2007;13(6):579-85.
2007: Kathryn Eagye; Joseph L Kuti; Michael Dowzicky; David P Nicolau
Empiric therapy for secondary peritonitis: a pharmacodynamic analysis of cefepime, ceftazidime, ceftriaxone, imipenem, levofloxacin, piperacillin/tazobactam, and tigecycline using Monte Carlo simulation.
Clinical therapeutics 2007;29(5):889-99.
2007: Aryun Kim; Joseph L Kuti; David P Nicolau
Review of dalbavancin, a novel semisynthetic lipoglycopeptide.
Expert opinion on investigational drugs 2007;16(5):717-33.
2007: Chonghua Li; Xiaoli Du; Joseph L Kuti; David P Nicolau
Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections.
Antimicrobial agents and chemotherapy 2007;51(5):1725-30.
2007: Su Young Lee; Joseph L Kuti; David P Nicolau
Cefepime pharmacodynamics in patients with extended spectrum beta-lactamase (ESBL) and non-ESBL infections.
The Journal of infection 2007;54(5):463-8.
2007: Carlos R V Kiffer; Joseph L Kuti; Caio Mendes; Carmen P Oplustil; Jorge B Amarante; Maria L Biancalana; Nelson Xavier; David P Nicolau
A pharmacodynamic strategy to optimize empirical antibiotic therapy for gram-negative bacteria in a Brazilian Intensive Care Unit.
The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases 2007;11(2):183-5.
2007: Kathryn Eagye; Joseph L Kuti; David P Nicolau
Evaluating empiric treatment options for secondary peritonitis using pharmacodynamic profiling.
Surgical infections 2007;8(2):215-26.
2007: C Andrew DeRyke; Mary Anne Banevicius; Hong Wei Fan; David P Nicolau
Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
Antimicrobial agents and chemotherapy 2007;51(4):1481-6.
2007: C Andrew DeRyke; Joseph L Kuti; David P Nicolau
Pharmacodynamic target attainment of six beta-lactams and two fluoroquinolones against Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, and Klebsiella species collected from United States intensive care units in 2004.
Pharmacotherapy 2007;27(3):333-42.
2007: C Andrew DeRyke; David P Nicolau
Is all free time above the minimum inhibitory concentration the same: implications for beta-lactam in vivo modelling.
International journal of antimicrobial agents 2007;29(3):341-3.
2007: Ioannis P Kioumis; Joseph L Kuti; David P Nicolau
Intra-abdominal infections: considerations for the use of the carbapenems.
Expert opinion on pharmacotherapy 2007;8(2):167-82.
2007: Heather K Sun; Xiaoli Du; C Andrew DeRyke; G V Doern; David P Nicolau
parE mutations in Streptococcus pneumoniae may reduce bactericidal activity of respiratory fluoroquinolones.
International journal of antimicrobial agents 2007;29(2):230-2.
2007: Christine T Ong; Pamela R Tessier; Chonghua Li; Charles H Nightingale; David P Nicolau
Comparative in vivo efficacy of meropenem, imipenem, and cefepime against Pseudomonas aeruginosa expressing MexA-MexB-OprM efflux pumps.
Diagnostic microbiology and infectious disease 2007;57(2):153-61.
2007: Kathryn Eagye; David P Nicolau; Shawn R Lockhart; John P Quinn; G V Doern; Gale Gallagher; Murray A Abramson
A pharmacodynamic analysis of resistance trends in pathogens from patients with infection in intensive care units in the United States between 1993 and 2004.
Annals of clinical microbiology and antimicrobials 2007;6():11.
2007: David P Nicolau; Christina A Sutherland; Adriano Arguedas; Ron Dagan; Micheal E Pichichero
Pharmacokinetics of cefprozil in plasma and middle ear fluid: in children undergoing treatment for acute otitis media.
Paediatric drugs 2007;9(2):119-23.
2007: Su Young Lee; Hong Wei Fan; Christina Sutherland; Andrew C DeRyke; David P Nicolau
Antibacterial effects of moxifloxacin and levofloxacin simulating epithelial lining fluid concentrations against community-acquired methicillin-resistant Staphylococcus aureus.
Drugs in R&D 2007;8(2):69-77.
2006: Su Young Lee; Pamela R Tessier; Christopher K Murphy; David P Nicolau
Bactericidal efficacy of ABI-0043, a novel rifamycin, in a murine pneumococcal pneumonia model.
The Journal of antibiotics 2006;59(12):804-7.
2006: Su Young Lee; Srividya Kotapati; Joseph L Kuti; Charles H Nightingale; David P Nicolau
Impact of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species on clinical outcomes and hospital costs: a matched cohort study.
Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America 2006;27(11):1226-32.
2006: C Andrew DeRyke; Christina Sutherland; Bo Zhang; David P Nicolau; Joseph L Kuti
Serum bactericidal activities of high-dose daptomycin with and without coadministration of gentamicin against isolates of Staphylococcus aureus and Enterococcus species.
Antimicrobial agents and chemotherapy 2006;50(11):3529-34.
2006: William K Lau; David Mercer; Kamal M Itani; David P Nicolau; Joseph L Kuti; Debra Mansfield; Adrian Dana
Randomized, open-label, comparative study of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infection.
Antimicrobial agents and chemotherapy 2006;50(11):3556-61.
2006: Chonghua Li; Joseph L Kuti; Charles H Nightingale; David P Nicolau
Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients.
Journal of clinical pharmacology 2006;46(10):1171-8.
2006: Carlos R V Kiffer; Joseph L Kuti; Kathryn Eagye; Caio Mendes; David P Nicolau
Pharmacodynamic profiling of imipenem, meropenem and ertapenem against clinical isolates of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. from Brazil.
International journal of antimicrobial agents 2006;28(4):340-4.
2006: Heather K Sun; David P Nicolau; Joseph L Kuti
Resource utilization of adults admitted to a large urban hospital with community-acquired pneumonia caused by Streptococcus pneumoniae.
Chest 2006;130(3):807-14.
2006: C Andrew DeRyke; Xiaoli Du; David P Nicolau
Evaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profile of moxifloxacin and levofloxacin against parC-containing isolates of Streptococcus pneumoniae.
The Journal of antimicrobial chemotherapy 2006;58(3):601-9.
2006: Su Young Lee; Hong Wei Fan; Joseph L Kuti; David P Nicolau
Update on daptomycin: the first approved lipopeptide antibiotic.
Expert opinion on pharmacotherapy 2006;7(10):1381-97.
2006: Joseph L Kuti; Christine Ong; Mathew Lo; David Melnick; Norberto E Soto; David P Nicolau
Comparison of probability of target attainment calculated by Monte Carlo simulation with meropenem clinical and microbiological response for the treatment of complicated skin and skin structure infections.
International journal of antimicrobial agents 2006;28(1):62-8.
2006: C Andrew DeRyke; Joseph L Kuti; Debra Mansfield; Adrian Dana; David P Nicolau
Pharmacoeconomics of continuous versus intermittent infusion of piperacillin-tazobactam for the treatment of complicated intraabdominal infection.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 2006;63(8):750-5.
2006: Heather K Sun; Kenneth Duchin; Charles H Nightingale; Jeng-Pyng Shaw; Julie Seroogy; David P Nicolau
Tissue penetration of telavancin after intravenous administration in healthy subjects.
Antimicrobial agents and chemotherapy 2006;50(2):788-90.
2006: Jennifer M Ellis; Joseph L Kuti; David P Nicolau
Pharmacodynamic evaluation of meropenem and cefotaxime for pediatric meningitis: a report from the OPTAMA program.
Paediatric drugs 2006;8(2):131-8.
2006: Su Young Lee; Joseph L Kuti; David P Nicolau
Polymyxins: older antibiotics for a new threat.
Connecticut medicine 2006;70(1):25-8.
2006: C Andrew DeRyke; Su Young Lee; Joseph L Kuti; David P Nicolau
Optimising dosing strategies of antibacterials utilising pharmacodynamic principles: impact on the development of resistance.
Drugs 2006;66(1):1-14.
2006: Xiaoli Du; Chonghua Li; Joseph L Kuti; Charles H Nightingale; David P Nicolau
Population pharmacokinetics and pharmacodynamics of meropenem in pediatric patients.
Journal of clinical pharmacology 2006;46(1):69-75.
2005: Joseph L Kuti; David P Nicolau
Making the most of surveillance studies: summary of the OPTAMA Program.
Diagnostic microbiology and infectious disease 2005;53(4):281-7.
2005: Jennifer M Ellis; Joseph L Kuti; David P Nicolau
Use of Monte Carlo simulation to assess the pharmacodynamics of beta-lactams against Pseudomonas aeruginosa infections in children: a report from the OPTAMA program.
Clinical therapeutics 2005;27(11):1820-30.
2005: Effie L Gillespie; Joseph L Kuti; David P Nicolau
Pharmacodynamics of antimicrobials: treatment optimisation.
Expert opinion on drug metabolism & toxicology 2005;1(3):351-61.
2005: Srividya Kotapati; Joseph L Kuti; Charles H Nightingale; David P Nicolau
Clinical implications of extended spectrum beta-lactamase (ESBL) producing Klebsiella species and Escherichia coli on cefepime effectiveness.
The Journal of infection 2005;51(3):211-7.
2005: Christine T Ong; Prachi K Dandekar; C Sutherland; Charles H Nightingale; David P Nicolau
Intrapulmonary concentrations of telithromycin: clinical implications for respiratory tract infections due to Streptococcus pneumoniae.
Chemotherapy 2005;51(6):339-46.
2005: Heather K Sun; Joseph L Kuti; David P Nicolau
Pharmacodynamics of antimicrobials for the empirical treatment of nosocomial pneumonia: a report from the OPTAMA Program.
Critical care medicine 2005;33(10):2222-7.
2005: Prachi K Dandekar; Pamela R Tessier; David J Farrell; Charles H Nightingale; David P Nicolau
Evaluation of telithromycin against Streptococcus pneumoniae with ribosomal mutations utilizing in vitro time-kill methodology.
International journal of antimicrobial agents 2005;26(4):331-4.
2005: Xiaoli Du; Chonghua Li; Heather K Sun; Charles H Nightingale; David P Nicolau
A sensitive assay of amoxicillin in mouse serum and broncho-alveolar lavage fluid by liquid-liquid extraction and reversed-phase HPLC.
Journal of pharmaceutical and biomedical analysis 2005;39(3-4):648-52.
2005: Christine T Ong; Chinedum Babalola; Charles H Nightingale; David P Nicolau
Penetration, efflux and intracellular activity of tigecycline in human polymorphonuclear neutrophils (PMNs).
The Journal of antimicrobial chemotherapy 2005;56(3):498-501.
2005: Heather K Sun; Su Young Lee; Mary Anne Banevicius; Xiaoli Du; Dana Maglio; David P Nicolau
Efficacy of pulsatile amoxicillin and clarithromycin dosing alone and in combination in a murine pneumococcal pneumonia model.
The Journal of antimicrobial chemotherapy 2005;56(3):559-65.
2005: Chonghua Li; Joseph L Kuti; Charles H Nightingale; Debra Mansfield; Adrian Dana; David P Nicolau
Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection.
The Journal of antimicrobial chemotherapy 2005;56(2):388-95.
2005: Dana Maglio; Joseph L Kuti; David P Nicolau
Simulation of antibiotic pharmacodynamic exposure for the empiric treatment of nosocomial bloodstream infections: a report from the OPTAMA program.
Clinical therapeutics 2005;27(7):1032-42.
2005: Joseph L Kuti; Sheryl Horowitz; Charles H Nightingale; David P Nicolau
Comparison of pharmacodynamic target attainment between healthy subjects and patients for ceftazidime and meropenem.
Pharmacotherapy 2005;25(7):935-41.
2005: Joseph L Kuti; David P Nicolau
Derivation of meropenem dosage in patients receiving continuous veno-venous hemofiltration based on pharmacodynamic target attainment.
Chemotherapy 2005;51(4):211-6.
2005: C Andrew DeRyke; Dana Maglio; David P Nicolau
Defining the need for new antimicrobials: clinical and economic implications of resistance in the hospitalised patient.
Expert opinion on pharmacotherapy 2005;6(6):873-89.
2005: Prachi K Dandekar; Peter Williams; Pamela R Tessier; David J Farrell; Charles H Nightingale; David P Nicolau
Assessment of the efficacy of telithromycin simulating human exposures against S. pneumoniae with ribosomal mutations in a murine pneumonia model.
International journal of antimicrobial agents 2005;25(6):530-4.
2005: C Andrew DeRyke; Joseph L Kuti; David P Nicolau
Questioning the paradigm: monotherapy vs combination antimicrobial therapy for treatment of Pseudomonas aeruginosa.
Connecticut medicine 2005;69(5):271-5.
2005: Effie L Gillespie; Joseph L Kuti; David P Nicolau
When "S" does not mean success: the importance of choice of antibiotic and dose on clinical and economic outcomes of severe infection.
Connecticut medicine 2005;69(4):203-10.
2005: Heather K Sun; Christine T Ong; Ambreen Umer; Dawn Harper; Steven Troy; Charles H Nightingale; David P Nicolau
Pharmacokinetic profile of tigecycline in serum and skin blister fluid of healthy subjects after multiple intravenous administrations.
Antimicrobial agents and chemotherapy 2005;49(4):1629-32.
2005: Srividya Kotapati; Joseph L Kuti; Erika C Geissler; Charles H Nightingale; David P Nicolau
The clinical and economic benefits of administering piperacillin-tazobactam by continuous infusion.
Intensive & critical care nursing : the official journal of the British Association of Critical Care Nurses 2005;21(2):87-93.
2005: Christine T Ong; Joseph L Kuti; David P Nicolau
Pharmacodynamic modeling of imipenem-cilastatin, meropenem, and piperacillin-tazobactam for empiric therapy of skin and soft tissue infections: a report from the OPTAMA Program.
Surgical infections 2005;6(4):419-26.
2005: Srividya Kotapati; Joseph L Kuti; David P Nicolau
Pharmacodynamic modeling of beta-lactam antibiotics for the empiric treatment of secondary peritonitis: a report from the OPTAMA program.
Surgical infections 2005;6(3):297-304.
2005: Su Young Lee; Joseph L Kuti; David P Nicolau
Antimicrobial management of complicated skin and skin structure infections in the era of emerging resistance.
Surgical infections 2005;6(3):283-95.
2005: Dana Maglio; Mary Anne Banevicius; Christina Sutherland; Chinedum Babalola; Charles H Nightingale; David P Nicolau
Pharmacodynamic profile of ertapenem against Klebsiella pneumoniae and Escherichia coli in a murine thigh model.
Antimicrobial agents and chemotherapy 2005;49(1):276-80.
2005: Pamela R Tessier; Holly M Mattoes; Prachi K Dandekar; Charles H Nightingale; David P Nicolau
Pharmacodynamic profile of telithromycin against macrolide- and fluoroquinolone-resistant Streptococcus pneumoniae in a neutropenic mouse thigh model.
Antimicrobial agents and chemotherapy 2005;49(1):188-94.
2005: Chonghua Li; Dawei Xuan; Ming Ye; Charles H Nightingale; David P Nicolau
Simultaneous analysis of piperacillin and tazobactam in rabbits: application to pharmacokinetic study.
Biomedical chromatography : BMC 2005;19(1):99-106.
2004: Dana Maglio; David P Nicolau
The integration of pharmacokinetics and pathogen susceptibility data in the design of rational dosing regimens.
Methods and findings in experimental and clinical pharmacology 2004;26(10):781-8.
2004: Chonghua Li; Christina A Sutherland; Charles H Nightingale; David P Nicolau
Quantitation of tigecycline, a novel glycylcycline [corrected] by liquid chromatography.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2004;811(2):225-9.
2004: Joseph L Kuti; Kerry M Moss; David P Nicolau; R Frederic Knauft
Empiric treatment of multidrug-resistant Burkholderia cepacia lung exacerbation in a patient with cystic fibrosis: application of pharmacodynamic concepts to meropenem therapy.
Pharmacotherapy 2004;24(11):1641-5.
2004: Heather Sun; Dana Maglio; David P Nicolau
Macrolide resistance in Streptococcus pneumoniae: mechanisms, patterns, and clinical implications of resistance.
Connecticut medicine 2004;68(9):571-6.
2004: Chinedum Babalola; Charles H Nightingale; David P Nicolau
Effect of adjunctive treatment with gamma interferon against Pseudomonas aeruginosa pneumonia in neutropenic and non-neutropenic hosts.
International journal of antimicrobial agents 2004;24(3):219-25.
2004: David P Nicolau
Optimizing Efficacy in CARTIs: introduction.
The Annals of pharmacotherapy 2004;38(9 Suppl):S7.
2004: Holly M Mattoes; Joseph L Kuti; George L Drusano; David P Nicolau
Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem.
Clinical therapeutics 2004;26(8):1187-98.
2004: Joseph L Kuti; Charles H Nightingale; David P Nicolau
Optimizing pharmacodynamic target attainment using the MYSTIC antibiogram: data collected in North America in 2002.
Antimicrobial agents and chemotherapy 2004;48(7):2464-70.
2004: Srividya Kotapati; David P Nicolau; Charles H Nightingale; Joseph L Kuti
Clinical and economic benefits of a meropenem dosage strategy based on pharmacodynamic concepts.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 2004;61(12):1264-70.
2004: Blair Capitano; David P Nicolau; Brian A Potoski; Karin E Byers; Michael Horowitz; Raman Venkataramanan; David L Paterson
Meropenem administered as a prolonged infusion to treat serious gram-negative central nervous system infections.
Pharmacotherapy 2004;24(6):803-7.
2004: Dana Maglio; Blair Capitano; Mary Anne Banevicius; Qiuming Geng; Charles H Nightingale; David P Nicolau
Differential efficacy of clarithromycin in lung versus thigh infection models.
Chemotherapy 2004;50(2):63-6.
2004: Carlos R V Kiffer; Caio Mendes; Joseph L Kuti; David P Nicolau
Pharmacodynamic comparisons of antimicrobials against nosocomial isolates of escherichia coli, klebsiella pneumoniae, acinetobacter baumannii and pseudomonas aeruginosa from the MYSTIC surveillance program: the OPTAMA Program, South America 2002.
Diagnostic microbiology and infectious disease 2004;49(2):109-16.
2004: Dana Maglio; Christine Ong; Mary Anne Banevicius; Qiuming Geng; Charles H Nightingale; David P Nicolau
Determination of the in vivo pharmacodynamic profile of cefepime against extended-spectrum-beta-lactamase-producing Escherichia coli at various inocula.
Antimicrobial agents and chemotherapy 2004;48(6):1941-7.
2004: Chinedum Babalola; Charles H Nightingale; David P Nicolau
Adjunctive efficacy of granulocyte colony-stimulating factor on treatment of Pseudomonas aeruginosa pneumonia in neutropenic and non-neutropenic hosts.
The Journal of antimicrobial chemotherapy 2004;53(6):1098-100.
2004: Prachi K Dandekar; Janice Tetreault; John P Quinn; Charles H Nightingale; David P Nicolau
Prevalence of extended spectrum beta-lactamase producing Escherichia coli and Klebsiella isolates in a large community teaching hospital in Connecticut.
Diagnostic microbiology and infectious disease 2004;49(1):37-9.
2004: Dana Maglio; Blair Capitano; Mary Anne Banevicius; Pamela R Tessier; Charles H Nightingale; David P Nicolau
Efficacy of clarithromycin against Streptococcus pneumoniae expressing mef(A)-mediated resistance.
International journal of antimicrobial agents 2004;23(5):498-501.
2004: Joseph L Kuti; Charles H Nightingale; R Frederic Knauft; David P Nicolau
Pharmacokinetic properties and stability of continuous-infusion meropenem in adults with cystic fibrosis.
Clinical therapeutics 2004;26(4):493-501.
2004: Prachi K Dandekar; Pamela R Tessier; Peter Williams; Cuilian Zhang; Charles H Nightingale; David P Nicolau
Determination of the pharmacodynamic profile of daptomycin against Streptococcus pneumoniae isolates with varying susceptibility to penicillin in a murine thigh infection model.
Chemotherapy 2004;50(1):11-6.
2004: Chinedum Babalola; Kalpana B Patel; Charles H Nightingale; David P Nicolau
Synergistic activity of vancomycin and teicoplanin alone and in combination with streptomycin against Enterococcus faecalis strains with various vancomycin susceptibilities.
International journal of antimicrobial agents 2004;23(4):343-8.
2004: Dawei Xuan; David P Nicolau; Charles H Nightingale
Population pharmacokinetics of gentamicin in hospitalized patients receiving once-daily dosing.
International journal of antimicrobial agents 2004;23(3):291-5.
2004: Blair Capitano; Holly M Mattoes; Eric Shore; Aidan O'Brien; Sidney S Braman; Chistina Sutherland; David P Nicolau
Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults.
Chest 2004;125(3):965-73.
2004: David P Nicolau
Clinical use of antimicrobial pharmacodynamic profiles to optimise treatment outcomes in community-acquired bacterial respiratory tract infections: application to telithromycin.
Expert opinion on pharmacotherapy 2004;5(2):229-35.
2004: Chonghua Li; David P Nicolau; Philip D Lister; Richard Quintiliani; Charles H Nightingale
Pharmacodynamic study of beta-lactams alone and in combination with beta-lactamase inhibitors against Pseudomonas aeruginosa possessing an inducible beta-lactamase.
The Journal of antimicrobial chemotherapy 2004;53(2):297-304.
2004: Joseph L Kuti; Srividya Kotapati; Peter Williams; Blair Capitano; Charles H Nightingale; David P Nicolau
Pharmacoeconomic analysis of amphotericin B lipid complex versus liposomal amphotericin B in the treatment of fungal infections.
PharmacoEconomics 2004;22(5):301-10.
2004: Christine T Ong; Joseph L Kuti; Charles H Nightingale; David P Nicolau
Emerging Pseudomonas aeruginosa resistance: implications in clinical practice.
Connecticut medicine 2004;68(1):11-5.
2004: Joseph L Kuti; Naomi R Florea; Charles H Nightingale; David P Nicolau
Pharmacodynamics of meropenem and imipenem against Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa.
Pharmacotherapy 2004;24(1):8-15.
2003: David P Nicolau
Optimizing outcomes with antimicrobial therapy through pharmacodynamic profiling.
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 2003;9(4):292-6.
2003: Blair Capitano; Dana Maglio; Mary Anne Banevicius; Charles H Nightingale; David P Nicolau
Bactericidal effect of cethromycin (ABT-773) in an immunocompetent murine pneumococcal pneumonia model.
International journal of antimicrobial agents 2003;22(6):588-93.
2003: Naomi R Florea; Srividya Kotapati; Joseph L Kuti; Erika C Geissler; Charles H Nightingale; David P Nicolau
Cost analysis of continuous versus intermittent infusion of piperacillin-tazobactam: a time-motion study.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 2003;60(22):2321-7.
2003: Joseph L Kuti; Prachi K Dandekar; Charles H Nightingale; David P Nicolau
Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem.
Journal of clinical pharmacology 2003;43(10):1116-23.
2003: Chonghua Li; Qiuming Geng; David P Nicolau; Charles H Nightingale
Simultaneous determination of ticarcillin and clavulanate in rabbit serum and tissue cage fluid by liquid chromatography.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2003;794(2):227-36.
2003: Dana Maglio; David P Nicolau; Charles H Nightingale
Impact of pharmacodynamics on dosing of macrolides, azalides, and ketolides.
Infectious disease clinics of North America 2003;17(3):563-77, vi.
2003: Prachi K Dandekar; Pamela R Tessier; Peter Williams; Charles H Nightingale; David P Nicolau
Pharmacodynamic profile of daptomycin against Enterococcus species and methicillin-resistant Staphylococcus aureus in a murine thigh infection model.
The Journal of antimicrobial chemotherapy 2003;52(3):405-11.
2003: JoCarol J McNabb; David P Nicolau; Julie A Stoner; Jack Ross
Patterns of adherence to antiretroviral medications: the value of electronic monitoring.
AIDS (London, England) 2003;17(12):1763-7.
2003: Prachi K Dandekar; Dana Maglio; Christina A Sutherland; Charles H Nightingale; David P Nicolau
Pharmacokinetics of meropenem 0.5 and 2 g every 8 hours as a 3-hour infusion.
Pharmacotherapy 2003;23(8):988-91.
2003: Blair Capitano; David P Nicolau
Evolving epidemiology and cost of resistance to antimicrobial agents in long-term care facilities.
Journal of the American Medical Directors Association 2003;4(3 Suppl):S90-9.
2003: Srividya Kotapati; Joseph L Kuti; Charles H Nightingale; David P Nicolau
Role of pharmacodynamics in designing dosage regimens for beta-lactams.
Connecticut medicine 2003;67(5):265-8.
2003: Dana Maglio; Renli Teng; Per T Thyrum; Charles H Nightingale; David P Nicolau
Pharmacokinetic profile of meropenem, administered at 500 milligrams every 8 hours, in plasma and cantharidin-induced skin blister fluid.
Antimicrobial agents and chemotherapy 2003;47(5):1771-3.
2003: David P Nicolau; Holly M Mattoes; Mary Anne Banevicius; Dawei Xuan; Charles H Nightingale
Pharmacodynamics of a novel des-F(6)-quinolone, BMS-284756, against Streptococcus pneumoniae in the thigh infection model.
Antimicrobial agents and chemotherapy 2003;47(5):1630-5.
2003: Joseph L Kuti; Dana Maglio; Charles H Nightingale; David P Nicolau
Economic benefit of a meropenem dosage strategy based on pharmacodynamic concepts.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 2003;60(6):565-8.
2003: Naomi R Florea; Joseph L Kuti; Charles H Nightingale; David P Nicolau
Treatment of Clostridium difficile-associated disease (CDAD).
Connecticut medicine 2003;67(3):153-5.
2003: Prachi K Dandekar; Nancy L Barrett; Charles H Nightingale; David P Nicolau
Utilization of extended-spectrum beta-lactamase (ESBL) detection systems in microbiology laboratories: survey of Connecticut hospitals from 1998-2002.
Connecticut medicine 2003;67(3):149-52.
2003: Naomi R Florea; Dana Maglio; David P Nicolau
Pleconaril, a novel antipicornaviral agent.
Pharmacotherapy 2003;23(3):339-48.
2003: Myo-Kyoung Kim; Charles H Nightingale; David P Nicolau
Influence of sex on the pharmacokinetic interaction of fleroxacin and ciprofloxacin with caffeine.
Clinical pharmacokinetics 2003;42(11):985-96.
2003: Blair Capitano; O Alice Leshem; Charles H Nightingale; David P Nicolau
Cost effect of managing methicillin-resistant Staphylococcus aureus in a long-term care facility.
Journal of the American Geriatrics Society 2003;51(1):10-6.
2002: Prachi K Dandekar; David P Nicolau
Pharmacodynamic considerations for the selection of oral cephalosporins in the treatment of rhinosinusitis.
Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery 2002;127(6 Suppl):S10-6.
2002: Joseph L Kuti; Thuy N Le; Charles H Nightingale; David P Nicolau; Richard Quintiliani
Pharmacoeconomics of a pharmacist-managed program for automatically converting levofloxacin route from i.v. to oral.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 2002;59(22):2209-15.
2002: Myo-Kyoung Kim; Wen Zhou; Pamela R Tessier; Dawei Xuan; Min Ye; Charles H Nightingale; David P Nicolau
Bactericidal effect and pharmacodynamics of cethromycin (ABT-773) in a murine pneumococcal pneumonia model.
Antimicrobial agents and chemotherapy 2002;46(10):3185-92.
2002: Dawei Xuan; Mary Anne Banevicius; Blair Capitano; Myo-Kyoung Kim; Charles H Nightingale; David P Nicolau
Pharmacodynamic assessment of ertapenem (MK-0826) against Streptococcus pneumoniae in a murine neutropenic thigh infection model.
Antimicrobial agents and chemotherapy 2002;46(9):2990-5.
2002: Myo-Kyoung Kim; Blair Capitano; Holly M Mattoes; Dawei Xuan; Richard Quintiliani; Charles H Nightingale; David P Nicolau
Pharmacokinetic and pharmacodynamic evaluation of two dosing regimens for piperacillin-tazobactam.
Pharmacotherapy 2002;22(5):569-77.
2002: Holly M Mattoes; Blair Capitano; Myo-Kyoung Kim; Dawei Xuan; Richard Quintiliani; Charles H Nightingale; David P Nicolau
Comparative pharmacokinetic and pharmacodynamic profile of piperacillin/tazobactam 3.375G Q4H and 4.5G Q6H.
Chemotherapy 2002;48(2):59-63.
2002: Pamela R Tessier; Myo-Kyoung Kim; Wen Zhou; Dawei Xuan; Chonghua Li; Min Ye; Charles H Nightingale; David P Nicolau
Pharmacodynamic assessment of clarithromycin in a murine model of pneumococcal pneumonia.
Antimicrobial agents and chemotherapy 2002;46(5):1425-34.
2002: Dana Maglio; Charles H Nightingale; David P Nicolau
Extended interval aminoglycoside dosing: from concept to clinic.
International journal of antimicrobial agents 2002;19(4):341-8.
2002: Edward M Grant; Joseph L Kuti; David P Nicolau; Charles H Nightingale; Richard Quintiliani
Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital.
Pharmacotherapy 2002;22(4):471-83.
2002: Joseph L Kuti; Blair Capitano; David P Nicolau
Cost-effective approaches to the treatment of community-acquired pneumonia in the era of resistance.
PharmacoEconomics 2002;20(8):513-28.
2002: M K Kim; Mary Anne Banevicius; MK Zhong; X Shi; M Hu; Charles H Nightingale; David P Nicolau
Clearance of quinupristin-dalfopristin (Synercid) and their main metabolites during continuous veno-venous hemofiltration (CVVH) with or without dialysis.
The International journal of artificial organs 2002;25(1):33-9.
2002: Prachi K Dandekar; Richard Quintiliani; Charles H Nightingale; David P Nicolau
Extended-spectrum beta-lactamases (ESBL).
Connecticut medicine 2002;66(1):13-5.
2001: Dawei Xuan; C Turley; Charles H Nightingale; David P Nicolau
Determination of BMS-284756, a new quinolone, in mouse serum by high-performance liquid chromatography with fluorescence detection.
Journal of chromatography. B, Biomedical sciences and applications 2001;765(1):37-43.
2001: JoCarol J McNabb; J W Ross; K Abriola; C Turley; Charles H Nightingale; David P Nicolau
Adherence to highly active antiretroviral therapy predicts virologic outcome at an inner-city human immunodeficiency virus clinic.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2001;33(5):700-5.
2001: Myo-Kyoung Kim; Dawei Xuan; Richard Quintiliani; Charles H Nightingale; David P Nicolau
Pharmacokinetic and pharmacodynamic profile of high dose extended interval piperacillin-tazobactam.
The Journal of antimicrobial chemotherapy 2001;48(2):259-67.
2001: Holly M Mattoes; Mary Anne Banevicius; D Li; C Turley; Dawei Xuan; Charles H Nightingale; David P Nicolau
Pharmacodynamic assessment of gatifloxacin against Streptococcus pneumoniae.
Antimicrobial agents and chemotherapy 2001;45(7):2092-7.
2001: David P Nicolau; JoCarol J McNabb; MK Lacy; Richard Quintiliani; Charles H Nightingale
Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia.
International journal of antimicrobial agents 2001;17(6):497-504.
2001: JoCarol J McNabb; Charles H Nightingale; Richard Quintiliani; David P Nicolau
Cost-effectiveness of ceftazidime by continuous infusion versus intermittent infusion for nosocomial pneumonia.
Pharmacotherapy 2001;21(5):549-55.
2001: Dawei Xuan; David P Nicolau; Charles H Nightingale; Richard Quintiliani
Circulating tumor necrosis factor-alpha production during the progression of rat endotoxic sepsis.
Chemotherapy 2001;47(3):194-202.
2001: KQ Bui; P G Ambrose; David P Nicolau; C D Lapin; Charles H Nightingale; Richard Quintiliani
Pharmacokinetics of high-dose meropenem in adult cystic fibrosis patients.
Chemotherapy 2001;47(3):153-6.
2001: David P Nicolau; CO Onyeji; Mary Anne Banevicius; J Li; Charles H Nightingale
Effects of adjunctive treatment with combined cytokines in a neutropenic mouse model of multidrug-resistant Enterococcus faecalis septicemia.
Pharmacotherapy 2001;21(3):275-80.
2001: Dawei Xuan; MK Zhong; Holly M Mattoes; KQ Bui; JoCarol J McNabb; David P Nicolau; Richard Quintiliani; Charles H Nightingale
Streptococcus pneumoniae response to repeated moxifloxacin or levofloxacin exposure in a rabbit tissue cage model.
Antimicrobial agents and chemotherapy 2001;45(3):794-9.
2001: Edward M Grant; MK Zhong; J F Fitzgerald; David P Nicolau; Charles H Nightingale; Richard Quintiliani
Lack of interaction between levofloxacin and oxycodone: pharmacokinetics and drug disposition.
Journal of clinical pharmacology 2001;41(2):206-9.
2001: Blair Capitano; Richard Quintiliani; Charles H Nightingale; David P Nicolau
Antibacterials for the prophylaxis and treatment of bacterial endocarditis in children.
Paediatric drugs 2001;3(10):703-18.
2000: JoCarol J McNabb; Richard Quintiliani; Charles H Nightingale; David P Nicolau
Comparison of the bactericidal activity of trovafloxacin and ciprofloxacin, alone and in combination with cefepime, against Pseudomonas aeruginosa.
Chemotherapy 2000;46(6):383-9.
2000: JoCarol J McNabb; Robert C Owens; Dawei Xuan; Richard Quintiliani; Charles H Nightingale; David P Nicolau
Comparison of azithromycin leukocyte disposition in healthy volunteers and volunteers with AIDS.
International journal of antimicrobial agents 2000;16(1):37-43.
2000: CO Onyeji; David P Nicolau; Charles H Nightingale; L Bow
Modulation of efficacies and pharmacokinetics of antibiotics by granulocyte colony-stimulating factor in neutropenic mice with multidrug-resistant Enterococcus faecalis infection.
The Journal of antimicrobial chemotherapy 2000;46(3):429-36.
2000: Dawei Xuan; J F Lu; David P Nicolau; Charles H Nightingale
Population pharmacokinetics of tobramycin in hospitalized patients receiving once-daily dosing regimen.
International journal of antimicrobial agents 2000;15(3):185-91.
2000: MK Lacy; P R Tessier; David P Nicolau; Charles H Nightingale; Richard Quintiliani
Comparison of vancomycin pharmacodynamics (1 g every 12 or 24 h) against methicillin-resistant staphylococci.
International journal of antimicrobial agents 2000;15(1):25-30.
2000: Edward M Grant; MK Zhong; P G Ambrose; David P Nicolau; Charles H Nightingale; Richard Quintiliani
Stability of meropenem in a portable infusion device in a cold pouch.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 2000;57(10):992-5.
2000: David P Nicolau; CO Onyeji; MK Zhong; Pamela R Tessier; Mary Anne Banevicius; Charles H Nightingale
Pharmacodynamic assessment of cefprozil against Streptococcus pneumoniae: implications for breakpoint determinations.
Antimicrobial agents and chemotherapy 2000;44(5):1291-5.
2000: M K Kim; David P Nicolau; Charles H Nightingale; Richard Quintiliani
Quinupristin/dalfopristin: a treatment option for vancomycin-resistant Enterococci.
Connecticut medicine 2000;64(4):209-12.
2000: JoCarol J McNabb; R Quintiliani; David P Nicolau; E Grant; Charles H Nightingale
Cost-effectiveness in the use of antibiotics.
Current clinical topics in infectious diseases 2000;20():24-42.
2000: KQ Bui; Mary Anne Banevicius; Charles H Nightingale; Richard Quintiliani; David P Nicolau
In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.
The Journal of antimicrobial chemotherapy 2000;45(1):57-62.
1999: David P Nicolau; Mary Anne Banevicius; Charles H Nightingale; Richard Quintiliani
Beneficial effect of adjunctive azithromycin in treatment of mucoid Pseudomonas aeruginosa pneumonia in the murine model.
Antimicrobial agents and chemotherapy 1999;43(12):3033-5.
1999: MK Lacy; David P Nicolau; Charles H Nightingale; A Geffken; R Teng; J Vincent; Richard Quintiliani
Oral bioavailability and pharmacokinetics of trovafloxacin in patients with AIDS.
Antimicrobial agents and chemotherapy 1999;43(12):3005-7.
1999: MK Lacy; David P Nicolau; Mary Anne Banevicius; Charles H Nightingale; Richard Quintiliani
Protective effect of trovafloxacin, ciprofloxacin and ampicillin against Streptococcus pneumoniae in a murine sepsis model.
The Journal of antimicrobial chemotherapy 1999;44(4):477-81.
1999: KQ Bui; JoCarol J McNabb; C Li; Charles H Nightingale; David P Nicolau
Mononuclear and polymorphonuclear leukocyte dispositions of clarithromycin and azithromycin in AIDS patients requiring Mycobacterium avium complex prophylaxis.
Antimicrobial agents and chemotherapy 1999;43(9):2302-4.
1999: CO Onyeji; KQ Bui; David P Nicolau; Charles H Nightingale; L Bow; Richard Quintiliani
Influence of adjunctive interferon-gamma on treatment of gentamicin- and vancomycin-resistant Enterococcus faecalis infection in mice.
International journal of antimicrobial agents 1999;12(4):301-9.
1999: CO Onyeji; KQ Bui; Robert C Owens; David P Nicolau; Richard Quintiliani; Charles H Nightingale
Comparative efficacies of levofloxacin and ciprofloxacin against Streptococcus pneumoniae in a mouse model of experimental septicaemia.
International journal of antimicrobial agents 1999;12(2):107-14.
1999: Pamela R Tessier; David P Nicolau; CO Onyeji; Charles H Nightingale
Pharmacodynamics of intermittent- and continuous-infusion cefepime alone and in combination with once-daily tobramycin against Pseudomonas aeruginosa in an in vitro infection model.
Chemotherapy 1999;45(4):284-95.
1999: E Grant; David P Nicolau; Charles H Nightingale; Richard Quintiliani
Continuous infusion of beta-lactam antibiotics.
Connecticut medicine 1999;63(5):275-7.
1999: CO Onyeji; Pamela R Tessier; Charles H Nightingale; F Vallee; David P Nicolau
Pharmacokinetics of ticlopidine in the rabbit.
The Journal of pharmacy and pharmacology 1999;51(4):393-6.
1999: MK Lacy; W Lu; X Xu; P R Tessier; David P Nicolau; Richard Quintiliani; Charles H Nightingale
Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection.
Antimicrobial agents and chemotherapy 1999;43(3):672-7.
1999: David P Nicolau; Pamela R Tessier; Charles H Nightingale
Beneficial effect of combination antiplatelet therapy on the development of experimental Staphylococcus aureus endocarditis.
International journal of antimicrobial agents 1999;11(2):159-61.
1999: CO Onyeji; David P Nicolau; Charles H Nightingale; L Bow
Interferon-gamma effects on activities of gentamicin and vancomycin against Enterococcus faecalis resistant to the drugs: an in vitro study with human neutrophils.
International journal of antimicrobial agents 1999;11(1):31-7.
1998: MK Lacy; Robert C Owens; X Xu; David P Nicolau; Richard Quintiliani; Charles H Nightingale
Comparison of bactericidal activity after multidose administration of clarithromycin, azithromycin, and ceruroxime axetil against Streptococcus pneumoniae.
International journal of antimicrobial agents 1998;10(4):279-83.
1998: JoCarol J McNabb; David P Nicolau; Richard Quintiliani; Charles H Nightingale
Trovafloxacin: fourth generation fluoroquinolone.
Connecticut medicine 1998;62(8):483-7.
1998: Richard Quintiliani; Paul G Ambrose; David P Nicolau; M A Richerson; KQ Bui; JoCarol J McNabb; Charles H Nightingale; Robert C Owens
Infectious Diseases Society of America position statement on infectious diseases physicians and hospital pharmacists: comment and editorial.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1998;27(1):229-31.
1998: MK Lacy; David P Nicolau; Charles H Nightingale; Richard Quintiliani
The pharmacodynamics of aminoglycosides.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1998;27(1):23-7.
1998: David P Nicolau; Y S Feng; A H Wu; S P Bernstein; Charles H Nightingale
Myoglobin clearance during continuous veno-venous hemofiltration with or without dialysis.
The International journal of artificial organs 1998;21(4):205-9.
1998: David P Nicolau; L Nie; P R Tessier; H P Kourea; Charles H Nightingale
Prophylaxis of acute osteomyelitis with absorbable ofloxacin-impregnated beads.
Antimicrobial agents and chemotherapy 1998;42(4):840-2.
1998: David P Nicolau; P R Tessier; Charles H Nightingale; Richard Quintiliani
Influence of adjunctive ticlopidine on the treatment of experimental Staphylococcus aureus endocarditis.
International journal of antimicrobial agents 1998;9(4):227-9.
1998: L Nie; David P Nicolau; P R Tessier; H P Kourea; B D Browner; Charles H Nightingale
Use of a bioabsorbable polymer for the delivery of ofloxacin during experimental osteomyelitis treatment.
Journal of orthopaedic research : official publication of the Orthopaedic Research Society 1998;16(1):76-9.
1997: Robert C Owens; Mary Anne Banevicius; David P Nicolau; Charles H Nightingale; Richard Quintiliani
In vitro synergistic activities of tobramycin and selected beta-lactams against 75 gram-negative clinical isolates.
Antimicrobial agents and chemotherapy 1997;41(11):2586-8.
1997: Robert C Owens; Charles H Nightingale; David P Nicolau
Ceftibuten: an overview.
Pharmacotherapy 1997;17(4):707-20.
1997: Dawei Xuan; David P Nicolau; Pamela R Tessier; L Bow; Richard Quintiliani; Charles H Nightingale
In vitro reduction of endotoxin concentrations with the 5S fragment of immunoglobulin G.
Antimicrobial agents and chemotherapy 1997;41(7):1512-6.
1997: Robert C Owens; K B Patel; Mary Anne Banevicius; Richard Quintiliani; Charles H Nightingale; David P Nicolau
Oral bioavailability and pharmacokinetics of ciprofloxacin in patients with AIDS.
Antimicrobial agents and chemotherapy 1997;41(7):1508-11.
1997: David P Nicolau; M A Banevicius; M N Marangos; M E Klepser; Richard Quintiliani; Charles H Nightingale
Influence of adjunct azithromycin on the mortality of experimental Pseudomonas aeruginosa sepsis.
International journal of antimicrobial agents 1997;8(4):239-41.
1997: MN Marangos; David P Nicolau; Richard Quintiliani; Charles H Nightingale
Influence of gentamicin dosing interval on the efficacy of penicillin-containing regimens in experimental Enterococcus faecalis endocarditis.
The Journal of antimicrobial chemotherapy 1997;39(4):519-22.
1997: Michael E Klepser; David P Nicolau; Richard Quintiliani; Charles H Nightingale
Bactericidal activity of low-dose clindamycin administered at 8- and 12-hour intervals against Staphylococcus aureus, Streptococcus pneumoniae, and Bacteroides fragilis.
Antimicrobial agents and chemotherapy 1997;41(3):630-5.
1997: MN Marangos; Z Zhu; David P Nicolau; Michael E Klepser; Charles H Nightingale
Disposition of ofloxacin in female New Zealand white rabbits.
Journal of veterinary pharmacology and therapeutics 1997;20(1):17-20.
1997: Michael E Klepser; MN Marangos; Z Zhu; David P Nicolau; Richard Quintiliani; Charles H Nightingale
Comparison of the bactericidal activities of piperacillin-tazobactam, ticarcillin-clavulanate, and ampicillin-sulbactam against clinical isolates of Bacteroides fragilis, Enterococcus faecalis, Escherichia coli, and Pseudomonas aeruginosa.
Antimicrobial agents and chemotherapy 1997;41(2):435-9.
1996: David P Nicolau; P R Tessier; Charles H Nightingale; Richard Quintiliani
Influence of ticlopidine on the development of experimental Staphylococcus aureus endocarditis.
International journal of antimicrobial agents 1996;7(4):271-4.
1996: David P Nicolau; Y J Feng; A H Wu; S P Bernstein; Charles H Nightingale
Evaluation of myoglobin clearance during continuous hemofiltration in a swine model of acute renal failure.
The International journal of artificial organs 1996;19(10):578-81.
1996: David P Nicolau; J W Ross; Richard Quintiliani; Charles H Nightingale
Pharmacoeconomics of Pneumocystis carinii pneumonia in HIV-infected and HIV-noninfected patients.
PharmacoEconomics 1996;10(1):72-8.
1996: Michael E Klepser; Z Zhu; David P Nicolau; Mary Anne Banevicius; P P Belliveau; J W Ross; L Broisman; Richard Quintiliani; Charles H Nightingale
Oral absorption of trimethoprim-sulfamethoxazole in patients with AIDS.
Pharmacotherapy 1996;16(4):656-62.
1996: David P Nicolau; Y J Feng; A H Wu; S P Bernstein; Charles H Nightingale
Swine model of continuous arteriovenous hemofiltration.
Laboratory animal science 1996;46(3):355-7.
1996: David P Nicolau; A H Wu; S Finocchiaro; E Udeh; M S Chow; Richard Quintiliani; Charles H Nightingale
Once-daily aminoglycoside dosing: impact on requests and costs for therapeutic drug monitoring.
Therapeutic drug monitoring 1996;18(3):263-6.
1996: P P Belliveau; CD Freeman; David P Nicolau; Charles H Nightingale; P R Tessier; Richard Quintiliani
Serum bactericidal activity of ceftizoxime and ceftriaxone against pathogens associated with community-acquired and nosocomial pneumonias.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 1996;53(9):1024-7.
1996: David P Nicolau; Charles H Nightingale; Mary Anne Banevicius; Q Fu; Richard Quintiliani
Serum bactericidal activity of ceftazidime: continuous infusion versus intermittent injections.
Antimicrobial agents and chemotherapy 1996;40(1):61-4.
1996: David P Nicolau; MN Marangos; Charles H Nightingale; K B Patel; B W Cooper; Richard Quintiliani; P Courvalin; R Quintiliani
Efficacy of vancomycin and teicoplanin alone and in combination with streptomycin in experimental, low-level vancomycin-resistant, VanB-type Enterococcus faecalis endocarditis.
Antimicrobial agents and chemotherapy 1996;40(1):55-60.
1995: Michael E Klepser; K B Patel; David P Nicolau; Richard Quintiliani; Charles H Nightingale
Comparison of the bactericidal activities of ofloxacin and ciprofloxacin alone and in combination with ceftazidime and piperacillin against clinical strains of Pseudomonas aeruginosa.
Antimicrobial agents and chemotherapy 1995;39(11):2503-10.
1995: MN Marangos; A T Skoutelis; Charles H Nightingale; Z Zhu; A G Psyrogiannis; David P Nicolau; H P Bassaris; Richard Quintiliani
Absorption of ciprofloxacin in patients with diabetic gastroparesis.
Antimicrobial agents and chemotherapy 1995;39(9):2161-3.
1995: CO Onyeji; Charles H Nightingale; Pamela R Tessier; David P Nicolau; L Bow
Activities of clarithromycin, azithromycin, and ofloxacin in combination with liposomal or unencapsulated granulocyte-macrophage colony-stimulating factor against intramacrophage Mycobacterium avium-Mycobacterium intracellulare.
The Journal of infectious diseases 1995;172(3):810-6.
1995: David P Nicolau; P P Belliveau; Charles H Nightingale; Richard Quintiliani; CD Freeman
Implementation of a once-daily aminoglycoside program in a large community-teaching hospital.
Hospital pharmacy 1995;30(8):674-6, 679-80.
1995: David P Nicolau; H Crowe; Charles H Nightingale; Richard Quintiliani
Bioavailability of fluconazole administered via a feeding tube in intensive care unit patients.
The Journal of antimicrobial chemotherapy 1995;36(2):395-401.
1995: L Nie; David P Nicolau; Charles H Nightingale; B D Browner; R Quintiliani
In vitro elution of ofloxacin from a bioabsorbable polymer.
Acta orthopaedica Scandinavica 1995;66(4):365-8.
1995: David P Nicolau; MN Marangos; Charles H Nightingale; Richard Quintiliani
Influence of aspirin on development and treatment of experimental Staphylococcus aureus endocarditis.
Antimicrobial agents and chemotherapy 1995;39(8):1748-51.
1995: David P Nicolau; Richard Quintiliani; Charles H Nightingale
Antibiotic kinetics and dynamics for the clinician.
The Medical clinics of North America 1995;79(3):477-95.
1995: Michael E Klepser; MN Marangos; K B Patel; David P Nicolau; Richard Quintiliani; Charles H Nightingale
Clinical pharmacokinetics of newer cephalosporins.
Clinical pharmacokinetics 1995;28(5):361-84.
1995: K B Patel; David P Nicolau; Charles H Nightingale; Richard Quintiliani
Pharmacokinetics of cefotaxime in healthy volunteers and patients.
Diagnostic microbiology and infectious disease 1995;22(1-2):49-55.
1995: David P Nicolau; CD Freeman; P P Belliveau; Charles H Nightingale; J W Ross; Richard Quintiliani
Experience with a once-daily aminoglycoside program administered to 2,184 adult patients.
Antimicrobial agents and chemotherapy 1995;39(3):650-5.
1995: MN Marangos; CO Onyeji; David P Nicolau; Charles H Nightingale
Disposition kinetics of aspirin in female New Zealand white rabbits.
Laboratory animal science 1995;45(1):67-9.
1995: David P Nicolau; Charles H Nightingale; P R Tessier; Q Fu; D W Xuan; E M Esguerra; Richard Quintiliani
The effect of fleroxacin and ciprofloxacin on the pharmacokinetics of multiple dose caffeine.
Drugs 1995;49 Suppl 2():357-9.
1994: CD Freeman; Charles H Nightingale; David P Nicolau; P P Belliveau; Mary Anne Banevicius; Richard Quintiliani
Intracellular and extracellular penetration of azithromycin into inflammatory and noninflammatory blister fluid.
Antimicrobial agents and chemotherapy 1994;38(10):2449-51.
1994: CD Freeman; Charles H Nightingale; David P Nicolau; P P Belliveau; Richard Quintiliani
Serum bactericidal activity of ceftriaxone plus metronidazole against common intra-abdominal pathogens.
American journal of hospital pharmacy 1994;51(14):1782-7.
1994: David P Nicolau; CD Freeman; Charles H Nightingale; C J Coe; Richard Quintiliani
Minocycline versus vancomycin for treatment of experimental endocarditis caused by oxacillin-resistant Staphylococcus aureus.
Antimicrobial agents and chemotherapy 1994;38(7):1515-8.
1994: David P Nicolau; H Crowe; Charles H Nightingale; Richard Quintiliani
Effect of continuous arteriovenous hemodiafiltration on the pharmacokinetics of fluconazole.
Pharmacotherapy 1994;14(4):502-5.
1994: CO Onyeji; David P Nicolau; Charles H Nightingale; Richard Quintiliani
Optimal times above MICs of ceftibuten and cefaclor in experimental intra-abdominal infections.
Antimicrobial agents and chemotherapy 1994;38(5):1112-7.
1994: P R Tessier; David P Nicolau; CO Onyeji; Charles H Nightingale
Caution in the use of commercial serum.
Laboratory animal science 1994;44(2):100.
1994: CO Onyeji; Charles H Nightingale; David P Nicolau; Richard Quintiliani
Efficacies of liposome-encapsulated clarithromycin and ofloxacin against Mycobacterium avium-M. intracellulare complex in human macrophages.
Antimicrobial agents and chemotherapy 1994;38(3):523-7.
1994: CD Freeman; Charles H Nightingale; David P Nicolau; P P Belliveau; P R Tessier; Q Fu; D W Xuan; Richard Quintiliani
Bactericidal activity of low-dose ceftizoxime plus metronidazole compared with cefoxitin and ampicillin-sulbactam.
Pharmacotherapy 1994;14(2):185-90.
1994: David P Nicolau; Richard Quintiliani
Choosing between the new cephalosporin antibiotics: a pharmacodynamic approach.
PharmacoEconomics 1994;5(Suppl 2):34-9.
1993: CD Freeman; David P Nicolau; P P Belliveau; Charles H Nightingale
Lomefloxacin clinical pharmacokinetics.
Clinical pharmacokinetics 1993;25(1):6-19.
1993: David P Nicolau; CD Freeman; Charles H Nightingale; Richard Quintiliani
Pharmacokinetics of minocycline and vancomycin in rabbits.
Laboratory animal science 1993;43(3):222-5.
1993: David P Nicolau; CD Freeman; Charles H Nightingale; Richard Quintiliani; C J Coe; E G Maderazo; B W Cooper
Reduction of bacterial titers by low-dose aspirin in experimental aortic valve endocarditis.
Infection and immunity 1993;61(4):1593-5.